spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

TAT 2018 Targeted Anticancer Therapies

European Society for Medical Oncology (ESMO)

5-7 March 2018
Paris Marriott Rive Gauche Hotel & Conference Centre

The constant evolution of early phase development and translational research drove ESMO to enrich its meeting portfolio by acquiring the TAT Congress and providing a discussion platform focusing on new molecular targets and innovative cancer therapeutics.

A prestigious scientific committee, led jointly by G. Giaccone and J. Tabernero, designed a cutting-edge programme, establishing the TAT 2018 Congress as the premier international anticancer drug development meeting bringing together academia, industry, clinicians, researchers, scientists and regulators.

The goals and the design of phase 1 studies have changed from just safety/toxicity to now include clinical activity/response and biomarker research. This new phase 1 paradigm has already led to rapid, conditional, approval of several new cancer therapeutics showing outstanding clinical activity in early-phase studies.

TAT focuses on early-phase development and translational research. The programme will cover targeted agents, immuno-oncology and combinations involving such agents. We hope to see you at TAT 2018!

phone +41 (0)91 973 19 00
email esmo@esmo.org
web www.esmo.org
 
Print this page
Send to a friend
   
spacer
Industry Events

Synthetic Biology Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its Synthetic Biology Congress taking place on 8-9 November 2018 in London. As part of our Genomics and Synthetic Biology UK series, our congress will bring together Over 600 delegates representing internationally renowned research & academic institutions, clinical research institutions and pharmaceutical companies.
More info >>

Banner of PHPL West Coast_events_95 on Samedan Banner of Nordics_Events_97 on Samedan

White Papers

The Importance of ADCC in Assessing Clinically Relevant Differences

Sartorius Stedim BioOutsource Ltd

Biosimilars have caused a revolution in the development of biologic drugs. The model for biosimilars is a combination of speed to market and low cost; these are fundamental to any biosimilar development project. The biosimilars pathway to approval is not always without difficulty, biosimilars are still relatively new, and as each new applicant is reviewed we are learning more and more about these molecules.
More info >>


News and Press Releases

Get on Board with a Neat Idea

Teknomek has launched a new range of anti-microbial shadow boards developed to meet the specific needs of the pharma sector. The products are made from PVC infused with Biomaster anti-bacterial silver-ion technology, which inhibits the growth of bacteria by up to 99.9%.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement